IMS Health announced its forecast for the emerging markets in pharma (dubbed “pharmerging”), predicting that 48% of overall industry growth will come from these countries in 2013.

It also increased the number of countries classed as pharmerging from seven to 17 and has classed them in three tiers of opportunity. The traditional emerging markets of China, Brazil, India and Russia form tiers one and two, but are now joined by Veneuzela, Poland, Argentina, Turkey, Mexico, Vietnam, South Africa, Thailand, Indonesia, Romania, Egypt, Pakistan and the Ukraine in tier three. South Korea has been moved out of this batch and is now classified as a developed market.

IMS forecasts that that the pharma market value across all three tiers of pharmerging countries will increase by $90bn between 2009 and 2013.

Ref: IMS Health
http://www.imshealth...mp;vgnextfmt=default

Can Western companies grasp the opportunity?